Ugo De Giorgi
机构: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS Meldola ITALY
每年引用次数
引用次数
引用: 25,585
H-指数: 78
I10-指数 : 335
出版物: 912
Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
G Procopio , M Prisciandaro , R Iacovelli , M Mancini
Annals of Oncology 28 vi18
2017
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
S Pignata , D Califano , D Lorusso , L Arenare
Annals of Oncology
2024
Intraoperative radiotherapy: current thinking
V Valentini , M Balducci , F Tortoreto , AG Morganti
European journal of surgical oncology 28 ( 2) 180 -185
58
2002
Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results
N Dizman , JE Rosenberg , JH Hoffman-Censits , DI Quinn
Liver 37 ( 15_suppl) 4510 -4510
9
2019
MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
S Pignata , D Lorusso , F Joly , C Gallo
The Lancet Oncology 22 267 -276
6
2021
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up☆
J Oldenburg , DM Berney , C Bokemeyer , MA Climent
Annals of Oncology 33 ( 4) 362 -375
88
2022
DOES BREAST CANCER AFFECT PROGNOSIS IN A BRCA-MUTATED OVARIAN CANCER COHORT? THE MITO 21 STUDY-A SUBGROUP ANALYSIS
L Borgato , A De Nicolo , D Lorusso , S Pignata
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 27 1450 -1450
2017
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
C Celsa , G Cabibbo , C AM Fulgenzi , B Scheiner
Digestive and Liver Disease 56 S76 -S78
2024
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study
Giovanni Li Volti , Giuseppe Di Lorenzo , Nicolò Borsellino , Gaetano Facchini
Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy
R Motzer , C Szczylik , NJ Vogelzang , CN Sternberg
European Journal of Cancer 49 S15 -S16
29
2013
Volume 34-No. 9-September 2023
U De Giorgi , EF Giunta , E Verzoni , G Procopio
Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
O Caffo , E Biasco , G Facchini , L Fratino
Annals of Oncology 27 iv31 -iv31
1
2016
Metabolic syndrome and inflammation in castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone (abi) and enzalutamide (enza)
V Conteduca , O Caffo , L Galli , A Maugeri
Annals of Oncology 28 v39 -v40
2017
When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting
G Procopio , L Porcu , P Grassi , U De Giorgi
Annals of Oncology 26 vi59 -vi59
2015
Treatment and Outcome (S) of a Large Cohort of Poor Risk Metastatic Renal Cell Carcinoma (Prrcc) Patients (Pts)
A Felici , D Santini , U De Giorgi , S Iacobelli
Annals of Oncology 25 iv290 -iv290
2014
Real world data from the Italian expanded access program (EAP): updated safety and efficacy results of nivolumab for metastatic renal cell carcinoma (mRCC)
U De Giorgi , G Cartenì , U Basso , L Galli
Associazione Italiana Oncologia Medica (AIOM) 2 -3
2017
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling–preliminary analysis of the INVIDIa study
M Bersanelli , P Castrignano , E Gambale , A Cortellini
Annals of Oncology 28 xi17 -xi17
4
2017
Activity of sequential new drugs (NDS) post-docetaxel (DOC) failure, in metastatic castration-resistant prostate cancer (mCRPC) patients (PTS). update from a multicenter Italian experience
O Caffo , U De Giorgi , L Fratino , G Facchini
Annals of Oncology 25 iv273 -iv273
3
2014
Effectiveness of Axitinib second-line therapy for metastatic renal cell carcinoma: preliminary results from real-word “SAX” observational study
S Rossetti , C D'Aniello , MG Vitale , A Farnesi
Annals of Oncology 27 iv36 -iv36
2016
Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: results from the MITO-9 study
A Bergamini , G Ferrandina , M Candiani , G Cormio
European Journal of Surgical Oncology 44 ( 6) 766 -770
28
2018